Helicobacter pylori infection
Conditions
Interventions
the bismuth-containing quadruple therapy (BQT) group:Esomeprazole 20 mg bid + bismuth potassium citrate 240 mg bid + amoxicillin 1.0 g bid + clarithromycin 500 mg bid for 14 days
KA Dual Therapy Group:Keverprazan 20 mg bid + amoxicillin 1.0 g bid for 14 days
KHA Dual Therapy Group:Keverprazan 20 mg bid + amoxicillin 1.0 g tid for 14 days
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years. 2. Confirmed H. pylori infection meeting any of the following criteria within the past 3 months: (1) positive ¹³C- or ¹4C-urea breath test with a value = twice the upper limit of normal; (2) positive histopathological examination or bacterial culture for H. pylori. 3. No previous history of H. pylori eradication therapy; patients who have taken anti-H. pylori medication for 5 consecutive days or more are considered to have received prior eradication therapy and will be excluded. 4. Willingness to participate in the study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to any of the drugs used in this study. 2. Patients who had history of gastric surgery. 3. Patients with insufficiency in vital organs, such as the lungs, heart, liver and kidneys. 4. Patients who had taken acid-suppressing drugs (such as potassium-competitive acid blockers, proton-pump inhibitors, or H2 receptor antagonists) within two weeks, or antibiotics, bismuth agents, or traditional Chinese medicine with antibacterial activity within four weeks before enrollment. 5. Pregnant women; lactating women who are unwilling to suspend breastfeeding during the study treatment period and within 2 days after the last dose; female subjects of childbearing potential who are unwilling to adopt medically approved effective contraceptive measures during the study period and within 4 weeks after the last dose. 6. Patients with psychiatric symptoms, drug addiction, severe neurocognitive disorders and other poor compliance or unable to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate of Helicobacter pylori;Adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance; | — |
Countries
China
Contacts
Public ContactZhang Jinyan
The First Affiliated Hospital of Xiamen University
Outcome results
None listed